Wissenschaftliche Publikationen
Die Leistungsfähigkeit des AKITA® JET Inhalationssystems und der FAVORITE Technologie ist mit zahlreichen klinischen Daten belegt, u.a.:
Studie mit 18 Lungenerkrankten (Asthma, COPD, Primär Ciliäre Dyskinesi, Sarkoidose) und 12 Lungen-gesunden Probanden
Brandt et al. 2000 Total deposition of therapeutic particles during spontaneous and controlled inhalations. Journal of Pharmaceutical Sciences, Vol. 89, No. 6.
Studie mit 18 COPD-Patienten
Scheuch et al. 2002 Regional drug targeting within the lungs by controlled inhalation with the AKITA inhalation
system, Drug Delivery to the Lungs Conference 2002 Edinburg, Schottland.
Studie mit 21 CF-Patienten
Griese et al. 2004 Improvement of Alveolar Gluthathione and lung function but not oxidative state in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, Vol. 169.
Studie mit 12 CF-Patienten
Brand et al. 2005 Optimum peripheral drug deposition in patients with cystic fibrosis
Studie mit 13 CF-Patienten
Köhler et. al. 2005 Lung deposition following electronically breath controlled inhalation and manually triggered conventional inhalation in CF patients; Journal of aerosol Medicine,Volume 18, no. 4, 2005, 386-395.
Studie mit 12 Lungen-gesunden Probanden
Brandt et al. 2006 Reduction of Drug-Dose and Therapy-Costs in high-dose Tobramycin-Inhalation, Journal of Cystic Fibrosis 2006; 5: suppl 1: 86 June 2006.
Studie mit 16 CF-Patienten
Dopfer et al. 2007 Inhalation of Tobramycin in Patients with Cystic Fibrosis: Comparison of two Different Methods; Journal of Physiology and Pharmacology, 2007, 58, suppl 5, 141-154.
Studie mit 112 Asthmapatienten
Jung et al. 2008 Treatment of Patients with uncontrolled Asthma using high dose inhaled Corticosteroids administered by controlled Inhalation - A retrospective Analysis. ERJ Volume 34 Supplement, 53 Sept 2009.
In-vitro-Studie mit verschiedenen Verneblersystemen
Müllinger et al. 2008 Drug Output of Inhalers is not a Predictor of Lung Dose, Inhaled Drug Delivery Conference, 12-13 Nov 2008, Sofitel St. James London.
Studie mit 39 CF-Patienten
Bakker et al. 2009 Peripheral deposition of inhaled rhDNase in CF patients during an exacerbation. Abstract of the 23rd Annual North American Cystic Fibrosis Conference 2009 (NACFC). October 15-17, 2009. Minneapolis USA.
Studie mit 6 Lungen-gesunden, 7 Patienten mit AAT-Mangel und 7 CF-Patienten
Brand et al. 2009 Lung deposition of inhaled alpha-1 proteinase inhibitor in cystic fibrosis and alpha-1 antitrypsin deficiency; Eur. Respir. J 2009; 34: 354-360
In-vitro-Studie mit verschiedenen Verneblersystemen
Kroneberg et al. 2010 The effect of different nebulizer systems in inhaled Tobramycin. ERS European Respiratory Society Conference, Barcelona, Spain, 18.-23. Sept. 2010 - Abstract ID 3505, Presentation ID E3505.
Invitro Studie mit rekombinantem GM-CSF
Luisetti et al 2010 Physical properties, lung deposition modeling, and bioactivity of recombinant GM-CSF aerosolised with a highly efficient nebulizer; Pulmonary Pharmacology & Therapeutics (2010) 1-5
Studie mit 49 CF-Patienten